Soft tissue sarcoma, version 2.2012: featured updates to the NCCN guidelines.

Journal Article (Journal Article)

The major changes to the 2012 and 2011 NCCN Guidelines for Soft Tissue Sarcoma pertain to the management of patients with gastrointestinal stromal tumors (GISTs) and desmoid tumors (aggressive fibromatosis). Postoperative imatinib following complete resection for primary GIST with no preoperative imatinib is now included as a category 1 recommendation for patients with intermediate or high risk of recurrence. The panel also reaffirmed the recommendation for preoperative use of imatinib in patients with GISTs that are resectable with negative margins but associated with significant surgical morbidity. Observation was included as an option for patients with resectable desmoid tumors that are small and asymptomatic, not causing morbidity, pain, or functional limitation. Sorafenib is included as an option for systemic therapy for patients with desmoid tumors.

Full Text

Duke Authors

Cited Authors

  • von Mehren, M; Benjamin, RS; Bui, MM; Casper, ES; Conrad, EU; DeLaney, TF; Ganjoo, KN; George, S; Gonzalez, R; Heslin, MJ; Kane, JM; Mayerson, J; McGarry, SV; Meyer, C; O'Donnell, RJ; Paz, B; Pfeifer, JD; Pollock, RE; Randall, RL; Riedel, RF; Schuetze, S; Schupak, KD; Schwartz, HS; Shankar, S; Van Tine, BA; Wayne, J; Sundar, H; McMillian, NR

Published Date

  • August 2012

Published In

Volume / Issue

  • 10 / 8

Start / End Page

  • 951 - 960

PubMed ID

  • 22878820

Electronic International Standard Serial Number (EISSN)

  • 1540-1413

Digital Object Identifier (DOI)

  • 10.6004/jnccn.2012.0099


  • eng

Conference Location

  • United States